Stock Ratings / Health Care / ADCT / financials

ZNTL (39) WHWK (28) YARW (41) SION (38) ⌘ Pro Terminal →

ADC Therapeutics SA (ADCT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.53 +2.69% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.53

ADC Therapeutics SA (ADCT) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $190.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADCT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ADCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, ADC Therapeutics SA (NYSE: ADCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.53 (+2.69% 1D, market cap $190.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ADCT ranks #744 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ADCT compare to ZNTL and WHWK in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADCT carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 92.9%, and ROIC of -35.0%. By comparison, ZNTL (Zentalis Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $188.4M) and WHWK (Whitehawk Therapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $188.1M). Among the 5-stock peer group, ADCT leads on earnings multiple (N/A) while SION leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADCT?

▼

Per ADCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001771910), ADC Therapeutics SA generated $81.4M in revenue (+14.9% YoY), -$142.6M in net income, and -$141.4M in free cash flow against $323.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.53 (+0.29%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADCT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY ADCT SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 53.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.73-19.1% Next Q

Q2 (-2Q)

Grade E$1.40+2.9% Next Q

Q3 (-1Q)

Grade E$1.44+6.3% Next Q

Current

Grade E$1.53-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ADCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ADCT currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.31) and Max Pain ($1.61) forces dealer call-delta covering toward $5.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ADCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ADCT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $69.1M

FY24

Rev $70.8M

FY25

Rev $81.4M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$81.4M	92.9%	-80%	-$142.6M	-$141.4M	-45%
FY 2024	$70.8M	91.6%	-80%	-$157.8M	-$124.7M	-45%
FY 2023	$69.1M	92%	-80%	-$240.1M	-$118.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADCT)

✓Walkthrough of ADCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.52%▲ ASCENDING CHANNEL

2026-10-30O $1.49H $1.54L $1.43C $1.53VOL 1.17M

RES: $1.96SUP: $1.13SMA50: $1.31SMA200: $2.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADCT Butterfly Map → + Track ADCT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +14.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADCT)

Health Care Rank #744 of 1016 ⚔️ ZNTL vs ADCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADCT vs. ZNTL, WHWK, YARW, SION)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ADC Therapeutics SA (ADCT) ranks #744 by composite RQD confidence (33/100, grade E) and #584 by equity capitalization ($190.2M). Within this direct 5-issuer industry benchmark cohort, ADCT leads on earnings valuation at N/A trailing P/E, while SION leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. YARW currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with ADCT at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADCT ACTIVE ADC Therapeutics SA	E	33/100	—	92.9%	-35.0%	+2.69%	$190.2M	Benchmark Subject
ZNTL Zentalis Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	-1.51%	$188.4M	/zntl-vs-adct →
WHWK Whitehawk Therapeutics Inc.	E	28/100	—	89.4%	-35.0%	-1.82%	$188.1M	/whwk-vs-adct →
YARW Yarrow Bioscience Inc.	D-	41/100	—	—	-35.0%	-0.50%	$186.1M	/yarw-vs-adct →
SION Sionna Therapeutics Inc.	D-	38/100	—	—	-28.3%	-3.25%	$180.8M	/sion-vs-adct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001771910

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ADC Therapeutics SA (ADCT) reported GAAP revenue of $81.4M (+14.9% vs. FY2024 revenue of $70.8M , and +17.8% cumulative change since FY2023) , GAAP net income of -$142.6M, operating cash flow of -$141.2M, and free cash flow of -$141.4M (-13.4% YoY). On the balance sheet, ADCT closed FY2025 with $323.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$81.4M	-$142.6M	-$141.2M	-$141.4M	$323.1M	—
FY2024 (FY)	2024-12-31	$70.8M	-$157.8M	-$123.8M	-$124.7M	$322.0M	—
FY2023 (FY)	2023-12-31	$69.1M	-$240.1M	-$118.7M	-$118.7M	—	—

3. ADCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ADCT compare to ZNTL and WHWK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ADCT?

Where is ADCT trading relative to its 50-day, 200-day, and 52-week technical levels?

ADCT last traded at $1.53 (+2.69% on volume of 1,175,406 shares), positioning the stock +16.79% above its 50-day simple moving average ($1.31) and -38.31% below its 200-day simple moving average ($2.48). Across its 52-week range of $0.78 to $4.98, ADCT sits at the 17.9% percentile with a 14-day RSI of 53.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.34 to $1.72).

ADCT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is ADC Therapeutics SA (ADCT)?

In FY 2025 (10-K), ADCT converted $81.4M of revenue into a 92.9% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ADCT RQD Cockpit ADCT 12M Forecast ADCT Earnings & Move ADCT Dividends & DRIP ADCT Insiders & 13F ADCT Whale Options ADCT Profit Sankey ADCT News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ADCT — ADC Therapeutics SA: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:41:31Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 33 out of 100, a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars break down as follows:

Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and FCF yield of 0%. For an investor, this indicates the business is not currently generating a return on invested capital or free cash flow to shareholders, so any valuation case rests on future cash generation rather than current earnings power.
Whale 13F Flow: 3 / 20. This pillar, which scores institutional accumulation and options positioning, is the weakest of the five. Per the Roarable RQD rating, it signals limited supportive institutional positioning in the source data.
Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider-conviction signals in the data.
Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. Market-level moves would be expected to pass through to the stock at roughly the market's own magnitude, with no defensive cushion indicated.
Forensic Balance Sheet: 11 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 5/9, and Debt/Equity is 0.5. These are the highest-scoring pillar but still sit in the middle of the range, indicating a balance sheet that is neither a clear strength nor an acute distress signal.

Practical implications for a prospective investor evaluating the stock today: the upside case depends on the business moving from deep operating losses toward cash generation, while the downside risks include continued cash burn, weak institutional and insider support, and high sensitivity to broader market swings. The stock's recent price move and restructuring headlines (see Recent Catalysts) do not by themselves change the cash-engine and flow pillars, which remain the primary drag on the score.

Business

ADC Therapeutics SA is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $81.4M for FY 2025, $70.8M for FY 2024, and $69.1M for FY 2023. Per the market data, gross margin is 92.9%.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$81.4M	$-121.5M	$-142.6M	N/A	$-141.4M	$261.3M	N/A
FY 2024	$70.8M	$-130.7M	$-157.8M	N/A	$-124.7M	$250.9M	N/A
FY 2023	$69.1M	$-166.0M	$-240.1M	N/A	$-118.7M	N/A	N/A

Per the market data, operating margin and net margin are both -60%, while gross margin is 92.9%, indicating high gross profitability that is overwhelmed by operating costs. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. Per the SEC financials, reported cash was $261.3M at FY 2025, up from $250.9M at FY 2024, while free cash flow remained negative in each reported year.

Recent Catalysts & News Wire Analysis

Per the news feed, the most recent headlines relate to a restructuring and its effect on the share price: one Seeking Alpha item (1h ago) describes shares spiking on restructuring while citing safety concerns, and a marketscreener.com item (9h ago) describes shares rising after a financial restructuring extended the cash runway. The feed flags the Seeking Alpha item as a CATALYST and the remaining items as MARKET WIRE.

Additional news-feed items include a MarketBeat report of an average target price of $5.00 (3h ago), a Stock Titan notice that full financial results will be posted online on Nov. 9 (6h ago), a MarketBeat report of a "Hold" rating from sell-side analysts (12h ago), and a Stock Titan report that Bain Capital reported 7 million shares plus warrants in ADCT (15h ago).

Risk watch items from the feed: the safety-related commentary in the Seeking Alpha headline and the Nov. 9 results-publication date. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector-level information is the classification as Health Care / Biotechnology: Pharmaceutical Preparations, and the beta of 1.0 per the market data.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. Holder data (Form 4, 13F, and Congressional trades) is not available in source data. The news feed references a MarketBeat report of an average target price of $5.00 and a sell-side "Hold" rating; these are headlines only and are not reflected in a structured analyst dataset. The feed also references a Bain Capital disclosure of 7 million shares plus warrants; this is a headline only and is not in the holder dataset.

Open Questions

What are the specifics of the restructuring referenced in the news feed, and what cash runway does it extend?
What safety concerns are referenced in the Seeking Alpha headline, and what is their scope?
What products and revenue sources generate the $81.4M of FY 2025 revenue?
What is the debt balance and its maturity profile, given the source data lists debt as N/A?
What EPS and valuation multiples apply, given the source data lacks P/E, EV/EBITDA, and EPS?

ADCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ADC Therapeutics SA (ADCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ADCT Debate Forum (3) ↓

🟢 CATALYST Seeking Alpha • 6h ago

ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis

Seeking Alpha report covering ADC Therapeutics SA (ADCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 9h ago

ADC Therapeutics SA (NYSE:ADCT) Stock Has Average Target Price of $5.00

MarketBeat report covering ADC Therapeutics SA (ADCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 12h ago

Full financial results will be posted online by ADC Therapeutics on Nov. 9.

Stock Titan report covering ADC Therapeutics SA (ADCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 15h ago

ADC Therapeutics Shares Rise After Financial Restructuring Extends Cash Runway

marketscreener.com report covering ADC Therapeutics SA (ADCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 18h ago

ADC Therapeutics SA (NYSE:ADCT) Stock Rated "Hold" by Sell-Side Analysts

MarketBeat report covering ADC Therapeutics SA (ADCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 21h ago

Bain Capital reports 7 million shares plus warrants in ADC Therapeutics (ADCT).

Stock Titan report covering ADC Therapeutics SA (ADCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

ADCT Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock Gain - Book Value Growth

https://www.dars.gov.et/ report covering ADC Therapeutics SA (ADCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 9h ago

ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company will report full financial results for the third quarter of

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADCT Bull vs. Bear Conversation Board — What's Your Call at $1.53?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADCT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.35 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ADCT (E • RQD 33/100) a Buy at $1.53?

Welcome to the ADCT (ADC Therapeutics SA) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.15 (-24.8%)

Spot @ $1.53

Pump the brakes on ADCT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ADCT, but look at what you are paying: current EV/EBITDA multiples with 92.9% gross margins. Unless ADC Therapeutics SA expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.96 (+28.1%)

Spot @ $1.53

ADCT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ADCT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.53 (52-wk range $0.78 - $4.98), any beat on forward guidance forces shorts and underweight funds to chase.